Myriad Genetics

🔒 Protecting Your Job Search: A Message from Myriad Genetics We have recently been made aware of unauthorized job postings falsely claiming to represent Myriad Genetics. Unfortunately, Myriad is just one of many companies whose identity has been misused by scammers to exploit job seekers. Here are some important reminders: 👉 Myriad Genetics will never request payment, solicit personal financial information, or conduct interviews through informal channels (e.g. via questionnaire, personal e-mail or text messages). 👉 All opportunity-related communication with Myriad Genetics will come from our employees, whose e-mail addresses end with "@myriad.com." We encourage all job seekers to visit our official Careers page below for verified opportunities: https://lnkd.in/grsdsAPB #teamMyriad #jobsearch #cybersecurity

👋 We're live at #ACMG2025! Stop by booth # 802 to meet some of #teamMyriad and learn about our industry-leading scientific innovations in genetics. #ACMG #innovation #genetictesting

Join Myriad Genetics for an informative webinar on March 26th at 1 PM ET about the impact of recent biomarker legislation, featuring insights from the American Cancer Society, Concert, and Hogan Lovells. 📣 Register now: https://lnkd.in/eqhE8Gf8 Biomarker testing provides essential insights for diagnosis, treatment optimization, and patient monitoring, ultimately improving clinical outcomes. This webinar will explore the role of biomarker testing in advancing healthcare equity, the legislative approach to ensuring coverage, the core components of biomarker legislation, and strategies for aligning coverage policies and payment with new laws. The roundtable discussion will focus on the implementation of biomarker coverage, collaboration with Medicaid programs, and discussion of practical steps for health plans to comply with legislative requirements that now exist in 20 states, as well as a Q&A with the speakers. 👉 Hilary Gee Goeckner, MSW, Director – State & Local Campaigns, American Cancer Society Cancer Action Network 👉 Gillian Hooker, Chief Scientific Officer, Concert 👉 Brian Carey, Partner Global Regulatory, Hogan Lovells 👉 Moderator: Paul Sheives, Vice President of Government Affairs, Myriad Genetics 🚨 Save your spot today: https://lnkd.in/eqhE8Gf8

"I work at Myriad Genetics as a Lead Clinical Genomic Scientist, supporting somatic testing with the goal of improving patient care. The theme #AccelerateAction for International Women's Day is a meaningful reminder of the progress made and the ongoing efforts needed to break down barriers and biases that women may face in their personal and professional lives. It inspires me to take thoughtful action in support of gender equality, recognizing the invaluable contributions of women across all areas of life, and working towards a future where they have opportunities and support to succeed. At Myriad Genetics, we are committed to advancing innovation in women's health through genetic testing solutions, including carrier screening, noninvasive prenatal screening, hereditary cancer testing, and breast cancer risk assessments. We also strive to foster a collaborative workplace where women feel supported and empowered to thrive." -Laura Gonzalez-Malerva; Lead Clinical Genomics Scientist, Clinical Genomics #teamMyriad #IWD2025 #WomensHistoryMonth

Myriad Genetics is leading the way for innovation in molecular diagnostic testing and precision medicine. Our commitment to accelerating scientific innovation is allowing us to deliver information to guide patients and providers on the path to better health. Sharing Myriad’s commitment to innovation, our Chief Technology Officer Kevin Haas was featured in a recent Medical Laboratory Observer article about how medical labs across the U.S. are embracing the digital transformation, saying: “At the meta level, the only thing that advances the speed of scientific discovery is increasing the iteration time by pulling in more data and performing more experiments faster. ... if I can go from testing one hypothesis a month to one hypothesis a day or an hour, that’s the promise of precision medicine.” Read the article here: https://brnw.ch/21wRnIz #GeneticTesting #GeneticInsights #PrecisionMedicine #innovation

Four brilliant minds took the stage at #ACRO25, leading an insightful panel on biomarkers and genetic testing in prostate cancer care. With a room full of engaged radiation oncologists from across the nation, the discussion highlighted: ✅ How biomarkers like Prolaris® guide treatment decisions ✅ The importance of germline testing in a comprehensive patient workup ✅ The future of genetic/genomic testing in personalizing care At Myriad Genetics, we are committed to supporting radiation oncologists and advancing precision medicine through our partnership with ACRO - American College of Radiation Oncology. #ProstateCancer #GeneticTesting #RadiationOncology #Biomarkers

Heading to Orlando, Florida next week for #PsychCongress? ☀️ The GeneSight team is gearing up for three days of great conversation and connection! Stop by booth #507 to chat about how genetic testing may tell you what your patients can't. 🧬 #NPInstitute2025 #MentalHealth

Exciting news from #ACRO25! 🎉 As a Gold Sponsor, we’re loving the enthusiasm at our booth from radiation oncologists who are interested in exploring genetic testing in prostate cancer. If you're attending, don’t miss the chance to stop by Booth #313 to learn more. We're looking forward to a great meeting! ACRO - American College of Radiation Oncology Sunny Yarrish Brooke Hart Terry White Rob Finch Michael Irelan Jef Reyburn, MBA #ProstateCancer #GeneticTesting #RadiationOncology #Biomarkers

We're gearing up for #ACMG2025 next week - We'll be sharing more about how our polygenic risk score includes answers for patients of all ancestries at our presentation on March 19th from 12:15 - 1:15 at Platform Session A. See you there! 📅 #ACMG #genetictesting

In the latest episode of the Precision Oncology and Prostate Cancer: The New Standard of Care miniseries, Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA, welcome special guest Dr. David Morris. These industry experts discuss how germline and somatic testing can help personalize treatment strategies and share real world case studies. Listen today! https://brnw.ch/21wRgab #ProstateCancer #GeneticTesting #GeneticInsights #PrecisionMedicine